HRP941018B1 - Highly concentrated immunoglobulin composition and method to prepare it - Google Patents

Highly concentrated immunoglobulin composition and method to prepare it

Info

Publication number
HRP941018B1
HRP941018B1 HRP4344824.0A HRP941018A HRP941018B1 HR P941018 B1 HRP941018 B1 HR P941018B1 HR P941018 A HRP941018 A HR P941018A HR P941018 B1 HRP941018 B1 HR P941018B1
Authority
HR
Croatia
Prior art keywords
highly concentrated
prepare
immunoglobulin composition
concentrated immunoglobulin
preparation
Prior art date
Application number
HRP4344824.0A
Other languages
English (en)
Inventor
Wolfgang Teschner
Original Assignee
Wolfgang Teschner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6506449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP941018(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wolfgang Teschner filed Critical Wolfgang Teschner
Publication of HRP941018A2 publication Critical patent/HRP941018A2/hr
Publication of HRP941018B1 publication Critical patent/HRP941018B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP4344824.0A 1993-12-28 1994-12-27 Highly concentrated immunoglobulin composition and method to prepare it HRP941018B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4344824A DE4344824C1 (de) 1993-12-28 1993-12-28 Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung

Publications (2)

Publication Number Publication Date
HRP941018A2 HRP941018A2 (en) 1997-04-30
HRP941018B1 true HRP941018B1 (en) 1999-12-31

Family

ID=6506449

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP4344824.0A HRP941018B1 (en) 1993-12-28 1994-12-27 Highly concentrated immunoglobulin composition and method to prepare it

Country Status (15)

Country Link
US (1) US5608038A (ru)
EP (1) EP0661060B1 (ru)
JP (1) JP3040678B2 (ru)
AT (2) AT407707B (ru)
CA (1) CA2138853A1 (ru)
CZ (1) CZ284186B6 (ru)
DE (2) DE4344824C1 (ru)
DK (1) DK0661060T3 (ru)
ES (1) ES2158877T3 (ru)
FI (1) FI111224B (ru)
HR (1) HRP941018B1 (ru)
HU (1) HU220766B1 (ru)
NO (1) NO315260B1 (ru)
RU (1) RU2104713C1 (ru)
YU (1) YU77994A (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1516628B1 (en) * 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
JP3919235B2 (ja) * 1997-06-13 2007-05-23 ジェネンテク，インコーポレイテッド 抗体製剤
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CA2490423A1 (en) * 2002-06-21 2003-12-31 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
ZA200507757B (en) * 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
MX2007000891A (es) * 2004-07-23 2007-04-18 Genentech Inc Cristalizacion de anticuerpos o fragmentos de ellos.
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2904458C (en) * 2007-11-30 2017-07-25 Wolfgang Fraunhofer Protein formulations and methods of making same
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
NZ606283A (en) * 2008-11-28 2014-08-29 Abbvie Inc Stable antibody compositions and methods for stabilizing same
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
RU2011140498A (ru) * 2009-03-06 2013-04-20 Дженентек, Инк. Препарат антител
PT2477603E (pt) 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
EP3345615B1 (en) 2010-03-01 2019-10-16 Bayer Healthcare LLC Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN110559435B (zh) 2013-09-11 2023-10-20 伊戈尔生物药品股份有限公司 包含离子性液体的液体蛋白质制剂
WO2015071348A1 (en) 2013-11-18 2015-05-21 Formycon Ag Pharmaceutical composition of an anti-vegf antibody
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
AU2015325055B2 (en) 2014-10-01 2021-02-25 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
RU2599029C1 (ru) * 2015-07-16 2016-10-10 Игорь Геннадьевич Ковшик Химерный иммуноглобулиновый препарат, обладающий специфическим противовирусным или антибактериальным действием
SI3334747T1 (sl) 2015-08-13 2024-02-29 Amgen Inc. Globinsko nabito filtriranje proteinov, ki vežejo antigen
EP3528787A4 (en) 2016-10-21 2020-05-06 Amgen Inc. PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075193A (en) * 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
AT359641B (de) * 1978-09-19 1980-11-25 Immuno Ag Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates
US4186192A (en) * 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
JPS57203017A (en) * 1981-06-09 1982-12-13 Fujirebio Inc Purifying method of immunoglobulin
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
DK166763C (da) * 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
EP0168506B2 (en) * 1984-07-07 1998-01-07 Armour Pharma GmbH Process for preparing gamma globulin suitable for intravenous administration
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
US5248767A (en) * 1986-06-11 1993-09-28 Behringwerke Aktiengesellschaft Process for the preparation of a pasteurized immunoglobulin preparation using ethanol
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
CH684164A5 (de) * 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.

Also Published As

Publication number Publication date
US5608038A (en) 1997-03-04
HU220766B1 (hu) 2002-05-28
YU77994A (sh) 1997-03-07
NO945045L (no) 1995-06-29
AT407707B (de) 2001-05-25
FI946104A (fi) 1995-06-29
FI946104A0 (fi) 1994-12-27
RU2104713C1 (ru) 1998-02-20
ATE201328T1 (de) 2001-06-15
DK0661060T3 (da) 2001-07-30
FI111224B (fi) 2003-06-30
HRP941018A2 (en) 1997-04-30
JPH07206709A (ja) 1995-08-08
EP0661060B1 (de) 2001-05-23
CZ328494A3 (en) 1995-07-12
DE59409761D1 (de) 2001-06-28
EP0661060A2 (de) 1995-07-05
HUT70449A (en) 1995-10-30
HU9403795D0 (en) 1995-02-28
CZ284186B6 (cs) 1998-09-16
JP3040678B2 (ja) 2000-05-15
CA2138853A1 (en) 1995-06-29
NO945045D0 (no) 1994-12-27
NO315260B1 (no) 2003-08-11
EP0661060A3 (de) 1997-01-15
DE4344824C1 (de) 1995-08-31
ES2158877T3 (es) 2001-09-16
ATA237894A (de) 2000-10-15

Similar Documents

Publication Publication Date Title
HRP941018B1 (en) Highly concentrated immunoglobulin composition and method to prepare it
CA2149150A1 (en) Injectable taxol composition with improved stability
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
AU4607589A (en) Antiperspirant compositions
PL314187A1 (en) Novel derivatives of pyrazine carboxamide, method of obtaining them and their application in pharmaceutical composition
GR3003631T3 (ru)
AU5652796A (en) Solid compositions containing polyethyleneoxide and a non-am orphous active principle
AU669122B2 (en) New pyrazine derivatives, their preparation and their use
AU6593094A (en) Fuel additives
ES2082424T3 (es) 1-aminonaftalenos sustituidos y composiciones estabilizadas.
DE69231020T2 (de) Succinoglycan enthaltende Zusammensetzung, Verfahren zu ihrer Herstellung und ihre Anwendungen
ZA91115B (en) Topical compositions
ES8301090A1 (es) Metodo de preparar agentes para la modificacion artificial de las precipitaciones atmosfericas.
BR9700840A (pt) Mistura de polisocianato de baixa viscosidade
AU8375891A (en) Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
NO943373L (no) Psyliumholdig sammensatt blandingsdrikk
EP0063328A3 (en) Compositions containing secretin and method for preventing the adsorption of secretin
ES2021334B3 (es) Composiciones de caucho que contienen derivados aminicos del 1,3,4-triadiazol.
AU7610194A (en) Thiocarbamoyl compounds used as antimicrobial agents
JPS6463342A (en) Stabilization of glutathione-containing composition
AU1508592A (en) Sweetening agents derived from l-glutamic acid and their method of preparation
AU3371593A (en) Highly concentrated amino acid solution
JPS6451488A (en) Fluid composition for automobile
DE3824939A1 (de) Neue 2,2-dihalogencyclopropylhydroxyethyltriazole enthaltende antimykotische mittel

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: BAXTER AKTIENGESELLSCHAFT, AT

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20001227

Year of fee payment: 7

PBON Lapse due to non-payment of renewal fee

Effective date: 20011228